CD274 and neoplasm: Atezolizumab significantly prolonged OS (20.2 versus 13.1 months; HR 0.59; 95% CI: 0.40–0.89, p = 0.0106) only in patients with high PD-L1 expression (PD-L1 ≥ 50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥ 10% of the tumor area) [34].